ONTARIO, Calif., June 14, 2004 (PRIMEZONE) -- LifePoint, Inc. (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced that the Barcelona Transit Authority has selected the LifePoint IMPACT Test System to routinely drug-test all drivers who are involved in serious accidents or cited for reckless driving.
Dr. Jose Miguel Gaona, Medical Director of Medical Europe Diagnostic stated, "Catalonia, one of the most advanced regions of Spain, is going to be the pioneer in the use, on a regular basis of the IMPACT Test System, which was chosen for it high level of accuracy and reliability as consistently demonstrated in product trials. I truly believe that the selection of IMPACT by Catalonia, should have great impact on the rest of the country, and serve as a model of excellence in transportation safety."
"We are pleased to announce that the LifePoint IMPACT Test System was chosen by the Spanish authorities in Barcelonia for use in Catalonia for drugged driver detection," stated Linda H. Masterson, President and CEO of LifePoint Inc. "This business win further validates the acceptance of the LifePoint's products in our served markets and we expect similar favorable test results on trials currently taking place elsewhere in Spain and in other European countries. We look forward to additional opportunities to gain further traction from our product sales in the European marketplace." Medical Europe Diagnostic distributes the product manufactured by LifePoint, Inc. in Spain.
About LifePoint, Inc.
LifePoint, Inc., a leader in non-invasive drug diagnostic technologies and solutions, has developed, manufactures and markets the IMPACT Test System -- a rapid diagnostic testing, screening and drug monitoring device for use in law enforcement and the workplace, and in the future, ambulances, pharmacies, and home healthcare markets. LifePoint's patented and proprietary technologies for the use of saliva as a non-invasive, blood-comparable test specimen, used in conjunction with the flow immunosensor technology licensed from the United States Navy, have allowed LifePoint to develop a broadly applicable, rapid, on-site diagnostic test system. The first product simultaneously detects drugs of abuse and alcohol. The initial three target markets -- law enforcement, industrial workplace and medical emergency room -- are estimated at over $1.6 billion in total sales opportunity.
This press release contains forward-looking statements regarding future events and the future performance of LifePoint, Inc. that involve risks and uncertainties that could cause actual results to differ materially. Although the Company believes that the expectations reflected in any forward-looking statements made herein are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company undertakes no obligation to update any forward-looking statements made to conform to actual results or to changes to expectations. These risks include, but are not limited to the potential need for additional financing, FDA 510(k) clearance in medical markets, dependence on third parties for certain marketing efforts, and market acceptance. These risks and others are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
LifePoint(r) and IMPACT(r) are trademarks of LifePoint, Inc.